A large trial found that hormone replacement therapy (HRT) increases the risk of death from lung cancer, especially non-small-cell lung cancer. Women taking HRT were 71% more likely to die from lung cancer than those on placebo, with higher risks also seen in current and long-term past smokers.
Researchers found that adding high-dose cytarabine to methotrexate therapy improved complete remission rates (46%) and overall response rates (69%) in patients with primary central nervous system lymphoma. The combination also resulted in a lower risk of relapse and improved progression-free survival.
A phase III randomised controlled trial found that dose-dense weekly paclitaxel plus carboplatin improved survival in women with advanced epithelial ovarian cancer, with a median progression-free survival of 28 months compared to 17 months. Overall survival at 3 years was also higher in the dose-dense regimen group.
A randomized phase III study found that pemetrexed significantly improved progression-free survival (4.3 months vs 2.6 months) and overall survival (13.4 months vs 10.6 months) compared to placebo in patients with advanced non-squamous NSCLC who did not progress after initial platinum-based chemotherapy.